<div id="readability-page-1"><p>Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) COO Peter Soparkar bought 50,000 shares of the company's stock in a transaction dated Friday, December 5th. The stock was bought at an average cost of $4.22 per share, for a total transaction of $211,000.00. Following the acquisition, the chief operating officer owned 80,189 shares of the company's stock, valued at approximately $338,397.58. This trade represents a 165.62% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.</p><h2>Adverum Biotechnologies Stock Up 2.3%</h2><p>Shares of NASDAQ ADVM traded up $0.10 during mid-day trading on Monday, hitting $4.36. 987,543 shares of the company were exchanged, compared to its average volume of 447,123. The stock has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $3.35. Adverum Biotechnologies, Inc. has a 1-year low of $1.78 and a 1-year high of $6.12. The firm has a market cap of $96.26 million, a price-to-earnings ratio of -0.51 and a beta of 0.87. </p><p>Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.80) by ($0.23).  Analysts anticipate that  Adverum Biotechnologies, Inc. will post -4.92 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities analysts have issued reports on the company. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Adverum Biotechnologies in a research report on Wednesday, October 8th. Truist Financial  set a $5.00 price target on shares of Adverum Biotechnologies in a research report on Friday, October 24th. Chardan Capital downgraded Adverum Biotechnologies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 27th. Mizuho  set a $5.50 target price on Adverum Biotechnologies in a research report on Wednesday, October 29th. Finally, HC Wainwright  reissued a &#34;neutral&#34; rating and issued a $5.00 target price (down previously from $30.00) on shares of Adverum Biotechnologies in a report on Monday, November 17th. One analyst  has rated the stock with a Buy rating, four have issued  a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat.com, Adverum Biotechnologies presently has a consensus rating of &#34;Hold&#34; and an average target price of $10.50.</p><p><b>Read Our Latest Stock Analysis on Adverum Biotechnologies</b></p><h2>Institutional Trading of Adverum Biotechnologies</h2><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BML Capital Management LLC increased its stake in shares of  Adverum Biotechnologies by 11.5% during the 2nd quarter. BML Capital Management LLC now owns 3,057,526 shares of the biotechnology company's stock valued at $6,574,000 after acquiring an additional 315,209 shares during the last quarter.  Pale Fire Capital SE boosted its position in shares of  Adverum Biotechnologies by 16.9% in the first quarter. Pale Fire Capital SE now owns 368,267 shares of the biotechnology company's stock worth $1,609,000 after acquiring an additional 53,113 shares during the last quarter.  Two Sigma Investments LP grew its holdings in  Adverum Biotechnologies by 372.7% in the third quarter. Two Sigma Investments LP now owns 88,670 shares of the biotechnology company's stock valued at $402,000 after purchasing an additional 69,913 shares during the period.  Jane Street Group LLC acquired a new position in  Adverum Biotechnologies during the second quarter worth approximately $153,000.  Finally, Invesco Ltd. purchased a new position in  Adverum Biotechnologies during the first quarter worth approximately $218,000. Hedge funds and other institutional investors own  48.17% of the company's stock. </p><h2>About Adverum Biotechnologies</h2> (Get Free Report)<p>Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Adverum Biotechnologies</li><li>Basic Materials Stocks Investing</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>3 Stocks Most Likely to Split in 2026</li><li>3 Warren Buffett Stocks to Buy Now</li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURWTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Adverum Biotechnologies Right Now?</h2><p>Before you consider Adverum Biotechnologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adverum Biotechnologies wasn't on the list.</p><p>While Adverum Biotechnologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ADVM

<p>Adverum Biotechnologies' COO, Peter Soparkar, purchased 50,000 shares of the company's stock for $211,000, increasing his position by 165.62%. The stock purchase was disclosed in an SEC filing. Following the transaction, Soparkar owns 80,189 shares valued at approximately $338,398. The company's stock rose 2.3% to $4.36. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and an average target price of $10.50. Institutional investors hold 48.17% of the company's stock.</p>

Adverum Biotechnologies (NASDAQ:ADVM) COO Purchases $211,000.00 in Stock